These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 19758663)

  • 21. Immunotherapeutic agents for the management of BCG refractory non-muscle invasive bladder cancer.
    Smaldone MC; Gingrich JR
    Minerva Urol Nefrol; 2010 Jun; 62(2):129-32. PubMed ID: 20562792
    [No Abstract]   [Full Text] [Related]  

  • 22. Friend or foe? Role of peroxisome proliferator-activated receptor-gamma in human bladder cancer.
    Inamoto T; Shah JB; Kamat AM
    Urol Oncol; 2009; 27(6):585-91. PubMed ID: 19162510
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Statins and the effect of BCG on bladder cancer.
    Kamat AM; Wu X
    N Engl J Med; 2007 Mar; 356(12):1276; author reply 1276-7. PubMed ID: 17377172
    [No Abstract]   [Full Text] [Related]  

  • 24. Editorial comment on: Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guérin immunotherapy.
    de Reijke TM
    Eur Urol; 2009 Jun; 55(6):1395-6. PubMed ID: 19193488
    [No Abstract]   [Full Text] [Related]  

  • 25. Is maintenance Bacillus Calmette-Guérin really necessary?
    Herr HW
    Eur Urol; 2008 Nov; 54(5):971-3. PubMed ID: 18585842
    [No Abstract]   [Full Text] [Related]  

  • 26. Re: Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer s. P. Lerner, C. M. Tangen, H. Sucharew, D. Wood and E. D. Crawford J Urol 2007; 177: 1727-1731.
    Lamm DL
    J Urol; 2008 Feb; 179(2):788. PubMed ID: 18082825
    [No Abstract]   [Full Text] [Related]  

  • 27. [ BCG-immunotherapy and bladder cancer].
    Rischmann P
    Prog Urol; 2008 May; 18 Suppl 5():S93. PubMed ID: 18585633
    [No Abstract]   [Full Text] [Related]  

  • 28. Editorial comment.
    Downs TM
    Urology; 2013 Jun; 81(6):1278. PubMed ID: 23528914
    [No Abstract]   [Full Text] [Related]  

  • 29. Editorial comment.
    Kassouf W
    J Urol; 2010 Aug; 184(2):469. PubMed ID: 20620400
    [No Abstract]   [Full Text] [Related]  

  • 30. Intravesical ICIs to reduce toxicity in NMIBC.
    Masone MC
    Nat Rev Urol; 2022 Dec; 19(12):694. PubMed ID: 36316466
    [No Abstract]   [Full Text] [Related]  

  • 31. [BCG maintenance treatment: an optimal scheme?].
    Xylinas E; Shariat SF
    Prog Urol; 2014 Jan; 24(1):1-2. PubMed ID: 24365621
    [No Abstract]   [Full Text] [Related]  

  • 32. Re: Agrawal et al.: The safety and efficacy of different doses of bacillus Calmette-Guérin in superficial bladder transitional cell carcinoma. (Urology 2007;70:1075-1078).
    Simone G; Leonardo C; Gallucci M
    Urology; 2008 Nov; 72(5):1187-8. PubMed ID: 18774592
    [No Abstract]   [Full Text] [Related]  

  • 33. [Ⅱ. Clinical Evidence and Biological Mechanism of BCG Failure in Patients with Non-Muscle Invasive Bladder Cancer].
    Miyake M
    Gan To Kagaku Ryoho; 2022 Jan; 49(1):33-38. PubMed ID: 35046358
    [No Abstract]   [Full Text] [Related]  

  • 34. Entrez into the immunogenetics of superficial bladder cancer response to bacillus Calmette-Guerin.
    O'Donnell M
    J Urol; 2006 Apr; 175(4):1197-8. PubMed ID: 16515958
    [No Abstract]   [Full Text] [Related]  

  • 35. The optimal management of T1G3 bladder cancer.
    Emiliozzi P; Pansadoro A; Pansadoro V
    BJU Int; 2008 Nov; 102(9 Pt B):1265-73. PubMed ID: 19035891
    [No Abstract]   [Full Text] [Related]  

  • 36. Editorial Comment to Recent advancements in the diagnosis and treatment of non-muscle invasive bladder cancer: Evidence update of surgical concept, risk stratification, and BCG-treated disease.
    Goto Y
    Int J Urol; 2023 Nov; 30(11):957-958. PubMed ID: 37608457
    [No Abstract]   [Full Text] [Related]  

  • 37. Re: Pathological Stage Review is Indicated in Primary pT1 Bladder Cancer.
    Wood DP
    J Urol; 2011 Feb; 185(2):468. PubMed ID: 22088626
    [No Abstract]   [Full Text] [Related]  

  • 38. [BCGitis].
    Husain-Syed F; Velcovsky HG
    Dtsch Med Wochenschr; 2006 Apr; 131(16):877-8. PubMed ID: 16625480
    [No Abstract]   [Full Text] [Related]  

  • 39. Is intravesical bacillus Calmette-Guérin better than mitomycin for intermediate-risk bladder cancer?
    Dalbagni G
    Eur Urol; 2009 Aug; 56(2):257-8; discussion 258-9. PubMed ID: 19427109
    [No Abstract]   [Full Text] [Related]  

  • 40. Bacillus Calmette-Guérin versus mitomycin C for the treatment of intermediate-risk non-muscle-invasive bladder cancer: the debate continues.
    Sylvester RJ
    Eur Urol; 2009 Aug; 56(2):266-8; discussion 268-9. PubMed ID: 19427110
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.